AC
LUCD icon

Ayrton Capital’s Lucid Diagnostics LUCD Stock Holding History

Ayrton Capital’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$86.5K Buy
+73,907
New +$107K 0.59% 18

Other funds holding LUCD

LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ayrton Capital's LUCD Position: Q3 2023 in Review

Ayrton Capital opened a new position in Lucid Diagnostics (LUCD) in Q3 2023: 73,907 shares worth $86.5K. The stake represents 0.59% of the portfolio and ranks #18 among its holdings.

24 funds tracked by Wall St. Rank hold LUCD as of Q3 2023.

  • Ayrton Capital held 73,907 shares of Lucid Diagnostics worth $86.5K as of Q3 2023.
  • Lucid Diagnostics was a new Ayrton Capital position in Q3 2023.
  • Lucid Diagnostics made up 0.59% of Ayrton Capital's portfolio in Q3 2023, its #18 holding.
  • 24 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2023.

Based on Ayrton Capital's 13F filing for Q3 2023, filed 13 Nov 2023.